A Methylation Profiling Diagnostic for Early Diagnosis of Alzheimer’s disease

Project Information

MAP-AD

Grant agreement ID: 960327

DOI

10.3030/960327

Project closed

EC signature date 24 August 2020

Start date 1 January 2021

End date 31 March 2024

Funded under

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Total cost

€ 3 568 650,00

EU contribution

€ 2 408 055,00

Coordinated by

ADMIT THERAPEUTICS S.L.
Spain

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Publications

Other (1)

15th Conference Clinical Trials Alzheimer’s Disease, November 29–December 2, 2022, San Francisco, CA, USA: Posters (Clinical Trial Alzheimer’s Disease). P50-Mitochondrial Methylcytosines as Novel Blood-Based Biomarkers for Prediction Progression to Alzheimer's Disease Dementia at the Mild Cognitive Impairment Stage: a Machine Learning Approach.

Author(s): J.L. Mosquera, M. Blanch, N. Rojo, I. Rico, J. Campdelacreu, B. Fontal, P. Ferrer, C. Fowler, S. Laws, A. Tort-Merino, R. Sanchez-Valle, R. Rene-Ramirez, J. Gascon, M. Barrachina
Published in: The Journal of Prevention of Alzheimer's Disease, Issue Volume 9 (Suppl 1), 2022, Page(s) S105-S106
Publisher: Serdi & Springer Nature
DOI: 10.14283/jpad.2022.97

Intellectual Property Rights

Patent (3)

METHODS OF DETERMINING THE RISK OF DEVELOPING ALZHEIMER'S DISEASE DEMENTIA

Application/Publication number: 20 23056250
Date: 2023-03-10
Applicant(s): ADMIT THERAPEUTICS S.L.

METHOD FOR IDENTIFYING DEMENTIA WITH LEWY BODIES IN A SUBJECT

Application/Publication number: 20 23068465
Date: 2023-07-04
Applicant(s): ADMIT THERAPEUTICS S.L.

MITOCHONDRIAL MARKERS OF NEURODEGENERATIVE DISEASES

Application/Publication number: 15 770042
Date: 2015-03-27
Applicant(s): ADMIT THERAPEUTICS S.L.